ArticleScientific reports2025
Dissolving porcine and human microthrombi by short exposure to microdoses of alteplase in an in vitro model of microvascular obstruction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advanced technologies of artery-on-a-chip: a review of construction strategies and disease models.Angiogenesis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Coronary microvascular obstruction (MVO) occurs in up to 57% of patients suffering from ST-segment elevation myocardial infarction (STEMI). One cause for MVO is distal embolization by microthrombi after percutaneous coronary intervention (PCI) of the infarct-related coronary artery. MVO is associated with an adverse cardiac prognosis post-STEMI. However, there are no evidence-based therapies for MVO, presenting an unmet therapeutic need. We investigated a novel pharmacotherapeutic approach to resolve embolizing MVO using an in vitro microfluidic model with porcine or human microthrombi to investigate thrombolysis with alteplase, a fibrinolytic drug. We show that a brief (90 s) exposure to concentrated microdoses of alteplase significantly reduces microthrombus size by up to 75%. 50% lysis occurred within six to twelve minutes after alteplase exposure depending on the initial microdose. Our results suggest that delivering a therapeutic drug directly to the microvasculature to briefly achieve high local drug concentrations has the potential to address embolizing MVO. The combination of short drug exposure and high local concentration is possible with a recently developed infusion system based on intracoronary controlled flow infusion (CoFI). CoFI uses microdoses of alteplase that are up to 1300 times lower than intravenous doses and could thereby minimize bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.